03:49 PM EST - Aurinia Pharmaceuticals Inc. : Has initiated a Rolling Submission of its New Drug Application to the U.S. Food and Drug Administration for voclosporin, a next-generation calcineurin inhibitor for the treatment of lupus nephritis. The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and expects to complete the submission of all Modules by the end of the second quarter of 2020. Aurinia Pharmaceuticals Inc.
shares T.AUP are trading down $1.88 at $16.47.